KRAS and cancer: Dual inhibition of mutant KRAS signalling is attractive, especially considering the observation that cancer cells can reactivate the MAPK pathway to resist G12C covalent inhibitors,25 molecules that trap the protein in the GDP state.21 Initial studies suggest that such compensatory mechanisms may not occur with KRpep-2d family members.